Gene-Based Therapeutics for Inherited Retinal Diseases

Area of Science:

• Ophthalmology
• Genetics
• Molecular Biology

Background:

• Inherited retinal diseases (IRDs) are a diverse group of rare genetic eye conditions.
• Monogenic mutations cause IRDs, making them prime candidates for gene-based therapies.
• Recent advancements, including approved therapies for Leber's congenital amaurosis, have spurred significant research.

Purpose of the Study:

• To review the therapeutic challenges associated with IRDs.
• To explore current and future gene-based therapeutic strategies for various IRD mutations.
• To highlight five distinct gene-based approaches with potential to treat the full spectrum of IRDs.

Main Methods:

• Review of existing literature on gene therapy for IRDs.
• Analysis of five distinct gene-based therapeutic strategies.
• Discussion of adeno-associated virus (AAV) and nonviral vectors for gene replacement.
• Exploration of CRISPR/Cas9 genome editing.
• Examination of RNA editing, antisense oligonucleotides, and optogenetics.

Main Results:

• Gene replacement using AAV and nonviral vectors is a key approach.
• Genome editing technologies like CRISPR/Cas9 offer precise gene correction.
• RNA editing and antisense oligonucleotides provide methods for modulating gene expression.
• Optogenetics presents a novel strategy to restore vision by engineering cellular function.
• These five approaches collectively address the heterogeneity of IRD mutations.

Conclusions:

• A range of gene-based therapies are being developed to combat IRDs.
• Gene replacement, genome editing, RNA editing, mRNA targeting, and optogenetics represent promising avenues.
• These innovative strategies hold potential to treat the diverse spectrum of inherited retinal diseases.